Evome Medical Technologies Inc.
LNDZF · OTC
12/31/2023 | 2/28/2022 | 2/28/2021 | 2/29/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.09 | 0.23 | -0.01 |
| FCF Yield | -7.61% | -15.45% | -14.49% | -2.36% |
| EV / EBITDA | -3.70 | -8.26 | -0.02 | 1.79 |
| Quality | ||||
| ROIC | -19.32% | -18.41% | -15.42% | -25.37% |
| Gross Margin | 35.98% | 32.56% | 36,914.62% | -5.77% |
| Cash Conversion Ratio | 0.06 | 0.85 | 0.37 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 273.26% | – | -55.29% |
| Free Cash Flow Growth | 0.00% | -264.81% | -704.73% | -103.20% |
| Safety | ||||
| Net Debt / EBITDA | -2.28 | -0.76 | 4.93 | 5.11 |
| Interest Coverage | -2.09 | -12.47 | -2.64 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.91 | 2.49 | 0.00 | 0.00 |
| Cash Conversion Cycle | 87.69 | 201.96 | -1,483.72 | -20.56 |